ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025

Core Insights - ImmuCell Corporation reported preliminary, unaudited sales results for Q3 2025, showing a decrease in sales compared to the same period in 2024 and the previous quarter [1][3] - The company has been providing preliminary sales results since Q1 2020 and plans to continue this practice [2] Sales Performance - Total sales for Q3 2025 were $5.5 million, down from $6.0 million in Q3 2024, representing an 8% decrease [3] - For the first six months of 2025, total sales reached $12.0 million, a 4% increase from $11.5 million in the same period of 2024 [3] - Total sales for the first nine months of 2025 were $20.0 million, up 7% from $18.7 million in 2024 [3] - Over the trailing twelve months, total sales increased to $27.8 million, a 16% rise from $23.8 million in the previous year [3] Inventory and Market Dynamics - The increase in sales during the first half of 2025 was attributed to the rebuilding of inventories of the First Defense product line after backlogs peaked in early 2024 [3][4] - The company anticipates a potential softening of sales in the second half of 2025 due to the re-stocking of distributor inventories [3][4] Product Development - ImmuCell is conducting a controlled study of its Investigational Product, Re-Tain, in collaboration with Michigan State University, which is expected to provide valuable data for treating mastitis in dairy cows [4] - The company submitted a Non-Administrative New Animal Drug Application (NADA) in early January 2025, with the remaining hurdle being the clearance of inspectional observations at its contract manufacturer's facilities [4] Future Outlook - The sales team is focused on regaining lost market share and is optimistic about sustainable long-term growth for the First Defense product line [4]